Gomez J, Suarez A, Lopez P, Mozo L, Diaz JB, Gutierrez C: Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features. Medicine (Baltimore) 85(3), 157-168 (2006). Antolin J ...

Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

Background A 23-year-old white woman with a 3-year history of systemic lupus erythematosus and a 15 ... Electroencephalogram showed no epileptiform features. The patient tested positive for ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Objective T cell receptor (TCR) diversity determines the autoimmune responses in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) and is closely associated with autoimmune diseases ...

population-based database to minimise the risk of selection and participation bias although clinical features and laboratory data, including anti-nuclear antibody and APS profiles, are not available ...

Remarkably, 65.52% of SLE patients reached SRI-4 response at the end of this study in low-dose IL-2 group, in comparison to 36.67% in the placebo group. Reduced SELENA-SLEDAI scores and resolution of ...